Unusual patterns of glycosylation on the surface of transformed cells contribute to immune modulation and metastasis of malignant tumors. Active immunization against them requires effective antigen presentation, which is complicated by a lack of access to tumor-specific posttranslational modifications through standard genetic approaches and by the low efficiency of passive antigen sampling. We found that antigen targeted to antigen presenting cells via class II MHC products can elicit a robust immune response against MUC1(Tn) bearing a defined tumor-associated glycoform, Tn. The two-component vaccine construct was prepared by sortase-mediated protein ligation of a synthetic MUC1(Tn) fragment to a class II MHC-binding singledomain antibody fragment (VHH7) as targeting moiety. We show that VHH7 targets antigen presenting cells in vivo, and when conjugated to MUC1(Tn) can elicit a strong aMUC1(Tn) immune response in mice.
Introduction
Mucin MUC1, a heavily glycosylated, polymorphic type-I transmembrane glycoprotein, contains an extracellular domain with a variable (10-100) number of tandem repeats (VNTRs), each composed of 20 amino acids (PDTRPAPGST APPAHGVTS A) with ve potential sites (underlined) for O-glycosylation. 1 The high density of branched O-linked glycans forces the protein backbone into an extended conformation, so that it protrudes from the apical surface of epithelial cells to form a protective mucous barrier. 2 In human adenocarcinomas such as breast, prostate, ovary and pancreatic cancers, MUC1 is overexpressed with loss of apical distribution, displaying truncated and immature glycosylation patterns due to the misregulation of core 1,3-galactosyltransferase (T-synthase) and a-N-acetylgalactosaminide a-2,6-sialyltransferase-1 (ST6GalNAc-1).
3 MUC1 promotes tumor dissemination by limiting E-cadherinmediated cell-cell and integrin-mediated cancer-matrix interactions. 4, 5 The extracellular domain of MUC1 also serves as a ligand for co-stimulatory intercellular adhesion molecule-1 (ICAM-1) and interferes with T cell activation and proliferation. Based on its surface availability, its widespread expressionincluding on cancer stem cells-and its intriguing function in driving immune tolerance, the National Cancer Institute has prioritized MUC1 as second among 75 tumor-associated antigens to be targeted for cancer vaccine development. 6 Approaches to create MUC1 vaccines have included epitopeprotein conjugates; multicomponent synthetic MUC1 peptide vaccines; MUC1 peptide-pulsed autologous dendritic cells; full or partially truncated MUC1 proteins; or MUC1-encoding plasmids, synthetic mRNA and viral vectors. [7] [8] [9] [10] Tumor epitopebased immunization is attractive as a means of reducing the risk of induced autoimmunity. As of today, it may be the only feasible strategy to induce a focused immune response against dened tumor-associated posttranslational modi-cations. However, small peptides are poorly immunogenic: to elicit an immune response they require conjugation to carrier proteins such as tetanus or diphtheria toxins. The size difference between carrier and conjugated peptide antigens usually causes a substantial portion of the response to be directed towards the carrier. Fully synthetic vaccines can provide solutions to these challenges, by integrating the minimal essential elements for eliciting stronger MUC1-specic immune responses in a dened and predictable manner. Such methods generally converge on nal steps that require the doping 9,11 or self-assembly 12,13 of dened vaccine constructs into macromolecular structures capable of multivalent presentation and accumulation in lymphoid organs.
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The low efficiency of passive antigen sampling poses yet an additional challenge for effective antigen presentation, which is required for CD8 T cell priming and critical to anti-tumor protection. Antigen delivery via antibodies that target antigenpresenting cells (APCs), especially via surface receptors that are endocytosed, enhances antigen loading and presentation, and therefore the efficacy of vaccines. It avoids the use of infectious or replicating materials, and provides a pure proteinbased vaccination strategy with minimal amounts of antigen. Full-sized antibodies that target class II major histocompatibility complex (MHC) products, 20 conjugated chemically or fused genetically to antigens, have all been reported to induce an immune response to the attached antigen. Epitopes with precise posttranslational modications are still excluded from this collection because a simple genetic fusion strategy cannot introduce the relevant specic glycoforms into the portions that comprise the relevant target antigen. The conserved and possibly heterogeneous N-glycan modications of the Fc domain of full-sized antibodies can also complicate the induction of a desired carbohydrate-specic response.
We reasoned that delivery of synthetic antigen via camelidderived heavy chain-only antibody fragments (VHHs) could address these drawbacks. VHHs, amenable to humanization, 21 are the smallest known antibody fragments that retain their antigen binding capacity. Individual VHHs (2.5 nm Â 2.5 nm Â 4 nm, 15 kDa) are almost $10 times smaller than a full-sized mAb (14.2 nm Â 8.5 nm Â 3.8 nm, 150 kDa), 22 facilitating penetration of lymphoid organs. Their single-domain congu-ration enables high-yield expression in bacterial systems in the absence of N-and O-glycosylation. 23 The C-terminus of a VHH is located opposite the complementarity-determining regions (CDRs) that confer binding specicity, making VHHs ideal substrates for installation of a sortase-recognition pentapeptide (LPXTG) motif to enable site-specic protein modication.
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We have screened and veried VHHs against various leukocyte surface markers such as class II MHC products, CD11b and CD36. Different antigenic payloads derived from GFP, ubiquitin, OVA peptide, and inuenza hemagglutinin's stem, at least when conjugated to these VHHs, elicited strong and characteristic immune responses. 27 In particular, VHH7, a VHH that recognizes murine class II MHC products with nanomolar affinity, stains class II MHC + populations such as dendritic cells (DCs), macrophages and B cells as analyzed by ow cytometry on excised organs. In vivo PET and NIR imaging conrmed the ability of VHH7 to target lymphoid organs. 28 Confocal microscopy showed internalization of VHH7 upon binding to class II MHC products. 29 Conjugation of a synthetic MUC1(Tn) epitope to VHH7 by means of a sortase reaction could thus provide a route to access structurally dened MUC1 vaccines with dened tumor-associated glycoforms. Directly targeting APCs would then drive a potent immune response against the attached payload. Fully synthetic payloads that cannot be encoded genetically would thus benet from the type of approach described here.
Here we report the preparation and in vivo application of a structurally dened MUC1(Tn) vaccine that preserves the immunogenic domain of MUC1 VNTR and a tumor-associated carbohydrate antigen Tn (aGalNAc-Thr/Ser). The Tn-antigen is a cancer-specic marker that can affect the conformation of the underlying peptide backbone and subsequent cancer-specic immune response. 30 To obtain the desired conjugate, a triglycine moiety was introduced at the N-terminus of the MUC1-VNTR-derived epitope to serve as a nucleophile and facilitate a sortase A (SrtA)-mediated transpeptidase reaction to obtain a structurally dened MUC1(Tn) epitope vaccine. Administration of these vaccine constructs to mice elicited strong humoral and cellular responses and was sufficient to establish long-term memory.
Results and discussion

Generate glycoform-dened VHH-MUC1(Tn) vaccine constructs
We chose the MUC1-derived epitope (TSAPDTRPAP) and extended it at the N-terminus with a triglycine moiety and a cysteine to allow bioconjugation through a sortase reaction and a thiol Michael addition, respectively. TSAPDTRPAP is the immunodominant segment of MUC1-VNTR. 9, 31, 32 We installed a tumor-associated carbohydrate antigen Tn at Thr6 (underlined). The carbohydrate moiety structurally inuences the underlying peptide backbone and can survive antigen processing. The processed glycoconjugate binds to class II MHC products via its peptide backbone, and is recognized by a specic T cell receptor. 33 This provides the rationale for inducing a tumor-specic immune response through T cell recognition of tumor-associated carbohydrate or glycopeptide antigens. The proper extent of glycosylation is critical for an optimal response. The O-glycosylation at a tumor-specic MUC1 epitope PDTRP enhanced the binding by available MUC1-specic monoclonal antibodies due to saccharide-induced conformational changes imposed on the peptide backbone. 34, 35 However, occupying all possible O-glycosylation sites impairs the antibody response, presumably because a heavily glycosylated MUC1 glycopeptide is processed less efficiently by APCs.
36,37
Although solid-phase peptide synthesis is a well established technology, the preparation of glycopeptides remains nontrivial. 38, 39 Our approach to the synthesis of oligoglycine-modied tumor-associated MUC1(Tn) epitope followed standard Fmocbased solid phase peptide synthesis on resin until the glycosylation site was reached, at which point the Fmoc-Thr-Tn(Ac) 4 building block with acetyl protected hydroxyl groups was coupled manually (Fig. 1a) . Aer coupling, the remaining free N-terminal amine was capped by excess acetic anhydride. The remainder of the sequence was then completed on a synthesizer, followed by cleavage off the resin and side-chain deprotection. O-glycans, in this case the Tn antigen are prone to b-elimination under standard Zemplén deacetylation conditions, resulting in low yields. For this reason, the remaining acetyl groups of the Tn antigen were removed by using a modied hydrazine protocol. 39, 40 Aer TFA deprotection and purication, the product was redissolved in 5% hydrazine aqueous solution for 1 h at room temperature, giving complete deacetylation without detectible elimination side products.
We next conjugated the (Gly) 3 -modied MUC1(Tn) to VHHs through a SrtA-mediated transpeptidase reaction. Besides VHH7, we used a VHH (Enh) specic for Enhanced Green Fluorescent Protein (EGFP) 41 as our specicity control. Both VHHs contain a Cterminal His 6 -tag preceded by a sortase recognition motif, LPETG. The sortase reactions were carried out following established protocols. 29 Purication of the desired product is simplied by adsorption of the reaction mixture onto Ni-NTA beads, which depletes His 6 -tagged sortase and any unreacted VHH that retained its His 6 tag, followed by size exclusion chromatography to remove excess nucleophile. The nal product yields a single peak on LC-MS. The expected sequence was conrmed by LC/MS/MS (Fig. 1c , S1e and f †). Site-specic conjugation using sortase has the advantage of convenient and unambiguous quality control. In contrast, our efforts to prepare BSA-MUC1(Tn) conjugates from commercially available maleimide-activated bovine serum albumin (BSA) resulted in a heterogeneous mixture, characterized by the presence of high-molecular weight material, presumably due to selfcrosslinking and variable quantities of attached peptide (Fig. 1b,  S1a and b †) .
Optimization of evoked humoral responses
With both VHH-MUC1(Tn) constructs in hand, we immunized mice and identied suitable adjuvants. Quillaja saponaria saponin (QS21), 42 polyinosinic-polycytidylic acid [p(I:C)] 43 and monophosphoryl lipid A (MPLA) 44 are all effective adjuvants that have been used clinically. Mice were immunized with a formulation composed of one of these adjuvants, VHH7-MUC1(Tn) conjugate, and a mAb against CD40. The latter is a potent B cell activator. Five days aer the nal immunization, blood was collected and tested for antibodies against MUC1(Tn) by ELISA. Inclusion of the adjuvant p(I:C) elicited the strongest immune response: the IgG response was ve-fold higher than for other adjuvants (compared at a 1/000 dilution). A lower IgM response was observed in the nal serum samples from the p(I:C) cohort, presumably owing to successful class switch recombination to other Ig isotypes, while QS21 and MPLA only provided modest anti-MUC1 responses, with no distinct preference for IgG (Fig. 2a and b) . The endpoint titer of IgG1 in the p(I:C) cohort was >1/10 5 dilution, with a comparable response for IgG2a (Fig. 2b) . A weak IgG3 response was observed for all formulations tested. This is likely determined by the steric conformation related to the combination of the carbohydrate portion and the polypeptide chain of MUC1(Tn), since in mice IgG3 is made exclusively in response to carbohydrate antigens.
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All further immunizations were conducted using the optimized adjuvant combination of anti-CD40 and p(I:C).
MUC1(Tn) is preferentially recognized
Since both VHH7-and Enh-MUC1(Tn) conjugates involve the use of small proteins (VHHs), we examined reactivity towards the VHH carriers, as distinct from that directed against the payload MUC1(Tn). Immunoblots (Fig. 3a) showed that the serum response was weak towards VHH7 with little cross reactivity to Enh, a llama-derived VHH used as fusion tag for immunoblot. The intense serum reactivity against Enh- MUC1(Tn) conjugate therefore must represent a strong response to its appended MUC1(Tn) epitope. In contrast, when mice were immunized with Enh-MUC1(Tn) conjugate (Fig. 3b) , the serum response was directed predominantly against Enh instead of MUC1(Tn), with similar signal intensities observed for Enh and Enh-MUC1(Tn), and only a weak signal for VHH7-MUC1(Tn). We attribute this difference to multivalent presentation of the VHH7-conjugated MUC1 epitope on the surface of APCs; however, the exact mechanism will be worthy of further investigation. In silico analysis of potential B epitopes by the Bepipred linear epitope prediction algorithm (Fig. S2 †) showed that the C-terminal MUC1 peptide is the dominant epitope predicted for B cell recognition in both VHH7-and Enh-MUC1 conjugates. Targeting of other antigenic payloads via VHH7 is likewise superior to the use of non-targeting VHHs. 27 We next examined to what extent the appended Tn moiety is recognized by the immune sera generated. A Chinese Hamster Ovary (CHO) ldlD cell line with defective UDP-galactose/UDP-Nacetylgalactosamine 4-epimerase cannot convert UDP-Glc/ GlcNAc to UDP-Gal/GalNAc, thereby rendering these mutant cells defective in protein O-/N-glycosylation reactions. When CHO-ldlD was stably transfected with a full-length MUC1 cDNA, the Tn epitope was generated only upon exogenous provision of GalNAc. 46 We cultured CHO-ldlD and CHO-ldlD-MUC1 with or without exogenously added GalNAc and tested sera from immunized mice for cell surface binding by ow cytometry. We detected MUC1-specic staining only in cells transfected with MUC1 cDNA. Cells supplemented with GalNAc displayed a further increase in staining intensity, consistent with better antibody recognition of Tn glycosylated MUC1 (Fig. 3c) . As expected, cells treated with GalNAc but not transfected with MUC1 were not recognized by the immune sera.
We further characterized the polyclonal response directed against synthetic MUC1 and MUC1(Tn) epitope by inhibition ELISA (Fig. 3d) . Reactivity of sera (dilution 1 : 200) from VHH7-MUC1(Tn)-immunized mice could be blocked with various concentrations of the MUC1(Tn) or the MUC1 epitope. An IC 50 of $1900 ng ml À1 was observed for the MUC1(Tn) epitope and an IC 50 of $6800 ng ml À1 for MUC1, which demonstrates a preference for the MUC1(Tn) epitope over the peptide backbone alone. Based on the chemical composition of the conjugate, only 0.5 mg carbohydrate antigen was injected to achieve this response, demonstrating the efficiency of directly targeting the antigen presentation pathway.
MUC1(Tn) positive cancer cells are recognized and killed by elicited sera
We tested serum reactivity in vitro against established cell lines known to express MUC1(Tn). Human breast and prostate cancer cell lines, MCF-7 and DU-145 respectively, were incubated with sera from VHH7-MUC1(Tn)-immunized mice at dilutions of 1/ 200 and 1/500, followed by secondary antibody staining with anti-mouse IgG-Alexa Fluor 647 (Fig. 4a) . Compared to control sera, ow cytometric analysis demonstrated strong reactivity of immune sera toward these cell lines. We explored antibodydependent complement-mediated lysis 10 and found that both cancer cell lines were efficiently and specically lysed (Fig. 4b) . Sera from control did not show cytolytic activity.
The VHH-MUC1(Tn) conjugate can activate both CD4 and CD8 T cells To achieve effective tumor eradication, help from CD4 T cells is required to prime and induce memory cytotoxic CD8 T cells. To assess the CD4 and CD8 T cell responses evoked by VHH7-directed antigen delivery, we conducted ex vivo stimulation of T lymphocytes from immunized mice. Antigen presenting cells were isolated from the spleens of naïve mice, pulsed with VHH7 or VHH7-MUC1(Tn) conjugates for antigen processing and presentation, then mixed in a ratio of 1 : 10 with T cells puried from previously immunized mice. MUC1-specic T cell activation was followed for two days by ow cytometric analysis of intracellular cytokine expression (Fig. 5) .
Production of Th1 (IFN-g, TNF-a) and Th2 (IL4) signature cytokines was examined. Antigen-specic CD4 and CD8 T cells were primed by incubation with antigen presenting cells (DCs or B cells) pulsed with the VHH7-MUC1(Tn) conjugate. Activation was observed within 24 h, and was accompanied by a 4-fold increase in the expression of the early activation marker CD69 (Fig. S3 †) . Even though less abundant, not surprisingly DCs were more effective than B cells at activating T cells, providing $5 times more cytokine induction. CD4 T cells from immunized animals produced high levels of IFN-g, a hallmark of Th1- : anti-murine IgG-AF647); (b) anti-MUC1 serum mediates effective complementdirected killing of MUC1-positive cancer cells (cells were incubated with serum (1 : 10) for 30 min, then medium was changed to 10% rabbit serum as a source of complement, followed by incubation for another 2 h. Cell viability was tested by MTT assay. Error bars: mean AE SD, n ¼ 3). polarized T cell activation. 47 As both CD4 and CD8 T cell responses were induced by VHH7-MUC1(Tn)-pulsed DCs, we conclude that cross-presentation of the antigen to class I MHC must have occurred. 48 
Memory response
The generation of long-term memory would be a highly desirable attribute for cancer vaccines. Although the exact requirements for generating and maintaining immune memory remain elusive, a strong primary immune response will generate a larger pool of cells from which to recruit memory cells. We analyzed the antibody response (Fig. S4 †) aer one or two boosts, using mice immunized with VHH7-MUC1(Tn) conjugate (4 injections) twelve months prior to the boost. A single boost effectively recalled the IgG1 response, as assayed by MUC1(Tn) ELISA compared to mice having completed only the initial immunization schedule. A second boost 7 days later did not further increase serum IgG1 levels.
Conclusions
The MUC1 epitope targeted here has been used both as a B cell 9 and a T cell 31 epitope. Improved design of vaccine constructs is required to overcome poor immunogenicity and obtain a strong humoral and cytotoxic immune response against the MUC1 epitope. The class II MHC-specic single-domain antibody fragment VHH7 is an effective vector to target a larger population of APCs, such as DCs, B cells and macrophages. When VHH7 is conjugated to a tumor-associated antigen, it binds to the surface of targeted cells, is processed and presented for B cell activation. Endocytosis of the VHH-class II MHC complex allows efficient loading of APCs with exogenous antigen and subsequent (cross) presentation. 49, 50 A strong and lasting immune response against MUC1(Tn) could thus be established. By targeting of antigen to different leukocyte surface markers responses can be skewed towards the B cell or T cell compartment, 27 the mechanistic details of which are worthy of further investigation.
The current vaccine constructs-completely structurally dened small protein conjugates-relied on the combined strengths of antibody engineering and chemical synthesis. The small, nonglycosylated, but fully functional VHHs that target APCs with low inherent immunogenicity minimized the response to the VHH carrier in the course of immunization, which is critical to obtain a focused immune response to tumor-specic epitopes. The sortase-mediated conjugation strategy conveniently modies protein vectors with synthetic payloads of choice. Chemical synthesis of glycosylated tumor-associated epitopes provides a gateway to access antigens with dened posttranslational modications. This strategy is a promising and straightforward method to generate focused immune responses towards epitopes with unique glycophenotypes. View Article Online
